Better results from
better imaging
At ImekaTM, we put patients first. That’s why we are committed to enhancing our clinical tools.
What we aim
to measure
ImekaTM’s
pipeline
Disease areas
What we aim to measure
At Imeka, we use non-invasive, advanced white matter MRI to image white matter and:
Measure three key markers of neuropathology: neuroinflammation, axonal degeneration, and demyelination;
Measure therapeutic effects, such as remyelination and
tissue repair;
Provide virtual dissection of 50+ different fiber bundles—robust to crossing fibers.
The ultimate goal of white matter imaging is to find non-invasive and indirect markers that are sensitive to pathology and can quantify damage and/or therapeutic changes. Imeka’s pipeline for ANDI achieves that goal.
ImekaTM’s pipeline, explained
Our highly sensitive technology identifies and quantifies:
ImekaTM’s biomarker and diagnostic potential
Imeka can give you precise micro- and macrostructure information about the white matter before clinical signs.
What if you could locate and measure the effect of a therapy before even seeing a clinical difference? What if you could quantify a clinical effect in a specific area of the brain, instead of having your data diluted by whole-brain measurements?
Imagine a future where a person can lie down in an MRI machine and find out if they’re slowly developing Parkinson’s disease. Or a patient can discover that their Alzheimer’s disease subtype is almost certain to respond to a specific therapy. We can identify such things for other diseases, like diabetes or gene-identified cancer. Let’s make this true in neurology, too.
DISEASE AREAS
We can identify and quantify neuroinflammation, axonal degeneration, and myelin indexes throughout the white matter and down to the fiber level.
These capabilities mean that Imeka has applications across the spectrum of central nervous system diseases, and we are always looking for exciting new things to discover.
Our biomarkers are most advanced in the following disease areas:
Alzheimer’s disease (AD)
There is a desperate need for better diagnostic tools and treatment options for AD. We believe our capabilities and biomarkers can make a real difference in the diagnosis and treatment of AD.
Here’s what we can see in AD:
Connections to and from the following regions:
- Medial temporal bundles
- Corpus callosum
- Posterior cingulum
Metrics:
- Neuroinflammation
- Axonal degeneration
- Myelin index
Multiple Sclerosis (MS)
White matter lesions traditionally define MS—but what is happening in the normal-appearing white matter? Our imaging and tracing abilities shed light on the mysteries of MS to help improve how we treat it.
Here’s what we can see in MS:
Pathologies that are:
- Lesion-load dependent and patient specific
- In the normal-appearing white matter
Metrics:
- Myelin index
- Neuroinflammation
- Axonal degeneration
Parkinson’s disease (PD)
The understanding and treatment of PD are both severely lacking. Better and earlier brain imaging can help us understand and learn to treat PD.
Here’s what we can see in PD:
Connections to and from the following regions:
- Substantia nigra
- Motor cortex
- Thalamus
- Brainstem
Metrics:
- Neuroinflammation
- Axonal degeneration
- Myelin index
Let’s collaborate!
Like you, our main goal is to play an influential role—and minimize risk—in the search for and development of cures for brain diseases. Let’s see what we can do together.